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concentration of the inhibitor 
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Figure 3.51 Lineweaver-Burk plot for S2 as inhibitor. [I] denoted the 
concentration of the inhibitor 
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Figure 3.52 Lineweaver-Burk plot for S3 as inhibitor. [I] denoted the 
concentration of the inhibitor 
 
 164 
Figure 3.53 Lineweaver-Burk plot for S4 as inhibitor. [I] denoted the 
concentration of the inhibitor 
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Figure 3.54 Mapping of potential inhibitors from NADI guided 
compounds on pharmacophoric model S5T5H06: (A) S1, 
C, Ki = 78 µM; (B) S2, NC, Ki = 232 µM; (C) S3, NC, Ki = 
97 µM and (D) S4, NC, Ki = 29 µM. HBD shown as violet 
sphere, HBA as light green sphere, Hbic as blue sphere, 
Ring Aromatic as orange sphere and excluded volume as 
grey spheres. C and NC signified competitive and non-
competitive, respectively 
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Figure 3.55 Suggested potential lead structure for the design of non-
competitive DEN-2 NS2B-NS3 protease inhibitor 
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PENEMUAN UBAT BERASASKAN LIGAN UNTUK PERENCAT 
NOVEL PROTEASE NS2B-NS3 DENGGI-2  
 
 
ABSTRAK 
 
Kes demam denggi dilaporkan meningkat setiap tahun, namun sehingga kini 
belum ada ubat anti-denggi boleh didapati di pasaran. Oleh itu, pencarian ejen anti-
denggi adalah kritikal. Pemotongan poliprotein pelopor oleh enzim protease NS2B-
NS3 merupakan proses yang sangat penting untuk replikasi flavivirus. Oleh itu 
enzim protease NS2B-NS3 sesuai dijadikan sasaran untuk membangunkan ubat anti-
denggi. Di Malaysia, Denggi-2 adalah jenis sera yang paling lazim. Dalam kajian ini, 
pendekatan berasaskan ligan telah dilaksanakan dalam mencari perencat enzim 
protease NS2B-NS3 Denggi-2 baharu yang berpotensi. Model farmakofor telah 
dihasilkan daripada pelbagai struktur perencat enzim protease NS2B-NS3 Denggi-2 
yang pernah dilaporkan, yang terdiri daripada molekul peptida dan bukan peptida. 
Model farmakofor terpilih telah digunakan untuk menyaring senarai sebatian dalam 
pengkalan data National Cancer Institute, AS (NCI) untuk mencari perencat protease 
NS2B-NS3 Denggi-2 yang baharu secara maya. Produk semulajadi dalam pengkalan 
data Natural Product Discovery System (NADI) juga disaring dan struktur yang aktif 
secara maya telah dieksploitasi untuk merekabentuk molekul perencat baru, yang 
kemudiannya disintesis. Aktiviti-aktiviti perencatan sebatian yang aktif secara maya 
dari pengkalan data NCI dan yang disintesis telah diuji secara biocerakinan in-vitro 
terhadap enzim protease NS2B-NS3 Denggi-2 menggunakan substrat peptida Boc-
Gly-Arg-Arg-MCA. Kewajaran pemilihan model farmakofor S5T5H06 dan 
S2T3H01 telah disahkan secara ujikaji dengan penemuan 3 perencat enzim protease 
NS2B-NS3 Denggi-2 baharu dari pengkalan data NCI dengan nilai-nilai Ki 17 ± 6 
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μM (perencat tidak kompetitif), 26 ± 4 μM (perencat kompetitif) dan 95 ± 35 μM 
(perencat kompetitif).  Disamping itu, 1 perencat kompetitif (Ki = 78 ± 41 μM) dan 2 
perencat tidak kompetitif (Ki = 29 ± 6 μM dan Ki = 97 ± 49 μM) telah diperolehi dari 
molekul yang disintesis berasaskan  struktur sebatian daripada pengkalan data NADI. 
Penemuan menarik ini mendedahkan bahawa produk semulajadi dari kepelbagaian-
bio Malaysia yang terdapat dalam pengkalan data NADI adalah sumber yang 
berharga untuk pembangunan ejen anti-denggi. Daripada keputusan ujikaji ini juga, 
satu andaian dapat dibuat iaitu ligan yang mempunyai farmakofor seperti model 
S5T5H06 boleh terikat kepada tapak ikatan aktif atau tapak ikatan alosterik dengan 
mod ikatan yang sama. Daripada kajian “SAR”, satu struktur pemula yang berpotensi 
untuk membangunkan perencat tidak kompetitif terhadap protease NS2B-NS3 
Denggi-2 telah dicadangkan. Struktur ini mempunyai nukleus pusat yang terdiri 
daripada di-fenilmetana. Nukleus pusat ini dihubungkan oleh kumpulan imina di 
kedudukan 1 dan 1' ke dua tangan fenil, R1 dan R2. Selain itu, struktur pemula ini 
perlu mempunyai kumpulan hidrofobik dan penerima ikatan hidrogen (HBA) sebagai 
rantaian sampingan kepada R1 dan penderma ikatan hidrogen (HBD) sebagai 
rantaian sampingan kepada R2. Berdasarkan keputusan-keputusan yang diperolehi, 
dapat disimpulkan bahawa farmakofor model S5T5H06 dan S2T3H01 boleh 
digunakan untuk pencarian perencat enzim protease NS2B-NS3 Denggi-2 yang 
berpotensi daripada pengkalan data kimia. Farmakofor model S5T5H06 dan 
S2T3H01 juga boleh dijadikan panduan untuk merekabentuk  perencat enzim 
protease NS2B-NS3 Denggi-2 berpotensi yang baru berdasarkan struktur sasaran 
yang aktif.        
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LIGAND BASED DRUG DISCOVERY OF NOVEL DENGUE-2 
NS2B-NS3 PROTEASE INHIBITORS 
 
ABSTRACT 
 
            The reported dengue cases are increasing yearly, yet no anti-dengue agent is 
available in the market. Therefore, the search for anti-dengue is critical. In Malaysia, 
Dengue-2 (DEN-2) is the most prevalent serotype. NS2B-NS3 protease is the 
enzyme for the cleavage of polyprotein precursor, which is crucial for the flavivirus 
replications. This makes it a potential target for the development of therapeutics 
against the dengue virus. In this study, ligand-based approach was implemented in 
searching for the new potential DEN-2 NS2B-NS3 protease inhibitors. 
Pharmacophore models were developed from diverse reported structures of DEN-2 
NS2B-NS3 protease inhibitors, comprising peptide and non-peptide molecules. The 
selected pharmacophore models were employed to screen the US National Cancer 
Institute (NCI) list of compounds to search for new DEN-2 NS2B-NS3 protease 
inhibitors. The list of natural products in Natural Product Discovery System (NADI) 
database was also screened and the structures of active hits were exploited for the 
design of new inhibitor molecules. The designed molecules were then synthesised. 
The in-vitro assay were conducted to examine the inhibitory activities of the selected 
hits from NCI database and the synthesised compounds towards recombinant DEN-2 
NS2B-NS3 protease by using fluorogenic peptide substrate Boc-Gly-Arg-Arg-MCA. 
The validity of selected pharmacophore models, S5T5H06 and S2T3H01 was 
experimentally established by the identification of three new DEN-2 protease 
inhibitors retrieved from NCI database with Ki values of 17 ± 6 μM (non-
competitive), 26 ± 4 μM (competitive) and 95 ± 35 μM (competitive). One 
competitive inhibitor (Ki = 78 ± 41 μM) and two non-competitive inhibitors (Ki = 29 
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± 6 μM and Ki = 97 ± 49 μM) were found from the NADI guided compounds. This 
interesting finding revealed that the natural products from Malaysian biodiversity, 
which are available in NADI database, are valuable resources of active 
compounds/active fragments for the development of anti-dengue. It was postulated 
that the active site and the allosteric binding site on DEN-2 protease share common 
binding mode to the ligand that carry the pharmacophores of the model S5T5H06. 
From SAR study, a potential lead structure for DEN-2 NS2B-NS3 protease non-
competitive inhibitor was suggested. The structure should has a central nucleus made 
up of diphenylmethane connected by imines at the position 1,1’ to two phenyl lateral 
arms, R1 and R2. Additionally, the structure should have a hydrophobic and a 
hydrogen bond acceptor (HBA) as side chains to the phenyl group R1 and a 
hydrogen bond donor (HBD) as a side chain to the phenyl group R2. The findings 
concluded that  pharmacophoric models S5T5H06 and S2T3H01 can be useful for 
pharmacophoric exploration of chemical databases in searching for the potential 
DEN-2 NS2B-NS3 protease inhibitors as well as a guide to design new potential 
inhibitors from the active hits. 
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1 CHAPTER 1  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 PROBLEM STATEMENT 
 
Dengue is the most prevalent arthropod-borne viral infection in human. It is 
estimated that dengue virus infection is 50 – 100 million per year globally in over 
100 tropic and sub-tropic countries where over 2.5 billion people (over 40% of 
world’s population) are at risk. Out of these 2.5 billion people at risk, 1.8 billion (> 
70%) are in Asia Pacific countries (Kumar et al., 2012; WHO, 2009, 2013a, 2013b). 
The trend of reported dengue cases in Western Asia Pacific region varies from region 
to region for example from 2006 to 2012, Australia, Cambodia, Lao PDR, Malaysia, 
Philippines and Vietnam have reported more cases in 2012 than in 2011. Malaysia in 
particular reported 21,900 of Dengue cases with 35 deaths (CFR 0.2%) for the year 
2012 compared to 19,884 cases (36 deaths, CFR 0.2%) in 2011 (WHO, 2013a). As at 
December 2013, Australia, Lao PDR, Malaysia, New Caledonia and Singapore have 
reported higher cumulative cases in 2013 compared to 2012 for the same time period 
(WHO, 2013c). In Malaysia, the cases rapidly increased (43346 cases with 92 death) 
by the end of 2013, which is two-fold increase relative to 2012 (WHO, 2014). Recent 
statistics of dengue cases and fatalities in Malaysia are ringing the alarm bells across 
the country. From 1
st
 to 22
nd
 January 2014, there were 6,155 dengue cases reported, 
compared to 1,792 cases within the same period in 2013 (six-fold increase). The 
number of deaths has doubled from five deaths in 2013 to 10 deaths in 2014, all 
within the same period (Ismail, 2014). 
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The continuous prevalent of dengue cases drive the researchers to search and 
develop the vaccine and anti-dengue drugs for the treatment of dengue.  The search 
for lead anti-dengue compounds has been done from many resources. In traditional 
medicines plants extracts,  several species have been reported with anti-dengue 
activity (Reis et al., 2008). A sulphated polysaccharide, named fucoidan, from 
marine algae  was found as a potential anti-dengue agent (Hidari et al., 2008) while 
there have been many discoveries of potential anti-dengue from synthetic compounds 
using many approaches such as in silico screening from compounds libraries 
(Kampmanna et al., 2009; Wang et al., 2009), high throughput in vitro screening and 
structure-based drug design (Tomlinson et al., 2009). 
 
                                  
                          
 
Figure 1.1: Several structures of potential anti-dengue compounds reported by 
Kampmanna et al., 2009 ((a) and (b)), Wang et al., 2009 (c) and Tomlinson et al., 
2009 ((d) and (e)). 
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Figure 1.1: Continued. 
 
From the understanding of the viral life cycle, the virus structural proteins 
(capsid protein, C, membrane-associated protein, prM and envelope protein, E) as 
well as non-structural proteins (NS1, NS2B, NS3 and NS5) have been identified as 
potential targets for the development of vaccine and anti-dengue drug. The 
development of imaging techniques, high resolution x-ray crystallography and 
computer simulation technology enable the proteins structure models of the virus to 
be available (Erbel et al., 2006) to assist researchers to understand the interactions of 
the target proteins and the drugs. This availability helps the researchers to speed up 
the finding of new drugs at lower cost.  
 
Nevertheless, the development of vaccines and antiviral therapy has seen little 
success where no licensed antiviral therapy is currently available (Sampath & 
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Padmanabhan, 2009). The control of disease is focused on the control of mosquito 
vector, which is costly and often met with limited success (Gubler, 1998). Therefore, 
the search for the lead compounds and derivatives with their information on the 
structures and activities is needed in discovering novel inhibitor for the development 
of anti-dengue. 
 
1.2 DENGUE 
 
Dengue is a disease caused by the infection of the dengue virus. There are 
four antigenically related but genetically distinct serotypes of dengue viruses; DEN-
1, DEN-2, DEN-3 and DEN-4, which are transmitted to human by female Aedes 
aegypti and Aedes albopictus mosquitoes. The symptom of a disease similar to 
dengue was reported since the end of 18
th
 century. In 1780, Benjamin Rush, a 
physician of Philadelphia, provided the first detailed description of what we know 
now as dengue fever. However, the first extensively documented outbreak of dengue 
haemorrhagic fever (DHF) occured in the Philippines in 1953 followed by Thailand 
in 1958. Since 1960s dengue has spread to over 60 countries (Howard, 2005). 
 
Dengue is most prevalent in tropical Asia, Latin America and Caribbean 
(Deen et al., 2006; Kyle & Harris, 2008; Mukhopadhyay, et al., 2005). From the 
estimated number of dengue virus infection of 50 – 100 million per year globally, 
250,000 – 500,000 patients develop more severe diseases of dengue haemorrhagic 
fever (DHF) and dengue shock syndrome (DSS) with 1-5% of cases result in fatality 
(Rawlinson et al., 2006). The incidence of dengue has increased dramatically in the 
past 50 years due to the population growth and uncontrolled urbanization in tropical 
and subtropical countries that become breeding sites for the mosquitoes and 
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problematic vector control (Kyle & Harris, 2008). In addition, the increased global 
transports networks such as air travel has enabled infected humans to spread viruses 
(Gibbons & Vaughn, 2002).  
 
Dengue symptoms appear after five to eight days following the bite by an 
infected mosquito (Smith, 1995). The person infected by dengue virus may manifest 
ranges of symptoms from silent infection (no symptom) to fatal dengue 
heamorrhagic fever (DHF)/ dengue shock syndrome (DSS) (Gibbons & Vaughn, 
2002). The WHO scheme has classified dengue virus infection into three categories; 
dengue fever, DHF and DSS. 
 
Dengue fever is clinically defined as an acute febrile illness with two or more 
manifestations (headache, retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic 
manifestations, leucopenia) and the occurrence should be at the same location and 
time as other cases of dengue fever. DHF is defined as a case that must meet all four 
of the following criteria: fever or history of fever lasting 2-7 days, a haemorrhagic 
tendency shown by a positive tourniquet test or spontaneous bleeding, 
thrombocytopenia and evidence of plasma leakage. DHF is further classified into 
four severity grades according to the presence or absence of spontaneous bleeding 
and the severity of plasma leakage. The dengue shock syndrome (DSS) refers to 
DHF grades III and IV, in which shock is present as well as all four DHF defining 
criteria (Deen et al., 2006; Gubler, 1998). Schematic of WHO classification of 
symptomatic dengue infection and WHO classification of dengue haemorrhagic fever 
are shown in Figure 1.2 and Table 1.1, respectively. 
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Figure 1.2: WHO classification of symptomatic dengue infection (Source: Deen et 
al., 2006). 
 
Among the infected person, less than 1% developed DHF/DSS. The 
development of DHF/DSS was influenced by many factors.  The patience with 
sequential infection of distinct dengue virus serotype from the primary infection 
showed to have 15-80-fold likely to develop DHF. However, patience that has not 
undergone a previous infection can also develop DHF. The trigger factors to the 
development of DHF could be host related such as age, sex, race, nutritional status 
and genetic predisposition. Children under 15 years old are more likely to develop 
DHF. However, in the case of DEN-2 outbreak in Santiago De Cuba in 1997, all 
DHF are in adults. Female are more likely to develop a more severe disease.  In the 
case of race factor, in Cuban epidemic in 1981, white Cubans were 3.5-fold more 
hospitalised compared to the black Cubans (Howard, 2005; Guzman, et al., 2006; 
Rawlinson et al., 2006). 
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Table 1.1: WHO classification of dengue haemorrhagic fever. Source: (Howard, 
2005). 
 
Grade Clinical description 
I Fever  with non-specific constitutional symptoms and the only 
haemorrhagic manifestations being a positive tourniquet test 
II As for Grade I, but accompanied by more extensive haemorrhagic 
manifestations 
III Sign of circulatory failure or hypertension  
IV Profound shock with pulse and blood pressure being undetectable  
 
Another trigger factor is the viral factor. The differences in genotype between 
strains also influence the severity of the disease. This phenomenon is shown by the 
capability of DEN-2 strain from Southeast Asia to cause DHF while the same strain 
did not cause DHF in epidemic event in Peru in 1995 even though  the population 
had undergone an epidemic of DEN-1 five years before. This is due to the fact that 
DEN-2 from Southeast Asia and Peru have differences in six amino acid in structural 
and non-structural proteins as well as at the 5’ and 3’ un-translated region of virus 
RNA. However, the exact factors for the minor cases of DHF/DSS development is 
still not clear (Rawlinson et al., 2006). 
 
1.3 DENGUE VIRUS 
 
Dengue virus is a member of Flaviviridae family from Flavivirus genera. The 
Flaviviridae family consists of three genera; Flavivirus, Pestivirus and Hepacivirus. 
Genus Flavivirus contains more than 70 viruses including dengue virus (DENV), 
Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), West Nile 
virus (WNV) and yellow fever virus (YFV). Dengue viruses are further divided into 
four serotypes 1, 2, 3 and 4 (DEN-1, DEN-2, DEN-3 and DEN-4).  
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1.3.1 The structure and genome of dengue virus 
 
Dengue virion is a spherical enveloped virus with diameter approximately 
500Å. It comprises a single, positive-strand RNA genome of ~10,700 nucleotides 
that is packed by three structural proteins and a lipid bilayer. The structural proteins 
are capsid, C; membrane-associated (M, which is expressed as prM, precursor to M) 
and envelope, E (Kuhn et al., 2002; Mukhopadhyay et al., 2005; Rey, 2003). The 
RNA of dengue virus consist of a 5’-untranslated region (UTR), a single open 
reading frame (ORF) and 3’-UTR (Dong et al., 2008). The RNA has type 1 cap at the 
5’-terminus (m7GpppAmp) and polyadenylate [Poly(A)] tail at 3’-terminus (Wahab 
et al., 2007). The three structural proteins (C, prM and E) are encoded by 5’- 
terminus of the ORF of the genome. The remainder of the ORF of the genome 
encodes seven nonstructural proteins i.e. NS1, NS2A, NS2B, NS3, NS4A, NS4B and 
NS5 (Figure 1.3).  
 
 
Figure 1.3: Schematic representation of flavivirus genome organization and 
polyprotein processing. Sites of polyprotein cleavage mediated by the viral NS2B-
NS3 and by host signalase are shown. The enzymatic activities of NS3 and NS5 are 
also indicated. Source: (Sampath & Padmanabhan, 2009)  
 
2K 
Hydrophobic peptide 
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1.3.2 Life cycle of Flavivirus 
 
The primary mammals’ cells infected by dengue virus are monocytes, 
macrophages and dendritic cells (Rawlinson et al., 2006; Sampath & Padmanabhan, 
2009). The life cycle of dengue virus and flavivirus in general, started with the 
attachment and binding of the virions on the host cell surface, followed by the entry 
into the cell by the process of endocytosis to form endosome. Endosome then  
undergoes the process of fusion where the RNA is released into the cytoplasm. The 
viral RNA is next translated into a polyprotein, which is cleaved into viral proteins 
(structural and non-structural) by polyprotein processing. Then, the replication of 
RNA and virus assembly occur. Finally, budding occurs where the new mature 
virions are released from the host cell by exocytosis (Guzman, et al., 2006; Lescar et 
al., 2008; Mukhopadhyay et al., 2005). The schematic diagram of the flavivirus life 
cycle is illustrated in Figure 1.4. 
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Figure 1.4: Flavivirus life cycle. Numbers shown in boxes refer to the pH of the 
respective compartments. Source: (Perera et al., 2008).  
 
1.3.2.1 Entry to the cell 
 
In the initial dengue virus infection process, the virion attaches to the host cell 
by the binding of E protein onto the receptor on the host cell surface (Rawlinson et 
al., 2006) . Then, the virion enters the cell by receptor-mediated endocytosis to form 
endosome (Sampath & Padmanabhan, 2009). There are different receptors for 
dengue virus on different cell types for the attachment. Fcɣ-R is the receptor for 
macrophages and monocytes, while the C-type lectine DC-SIGN(CD209) is the 
receptor for dendritic cell for the infection of all four dengue serotypes (Rawlinson et 
al., 2006). 
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Following endocytosis, the RNA genome is released into the cytoplasm of the 
host cell through the fusion of the viral membrane and the host-cell endosomal 
membrane. Acidic environment (low pH) in endosome mediates the structural 
reorganization of E protein (Sampath & Padmanabhan, 2009) from homodimers into 
homotrimers (Rawlinson et al., 2006). The trimeric conformation of the E protein 
forms more open structure, exposing the fusion peptide, thereby bringing the viral 
and endosomal membrane into close proximity and allowing insertion of the virus 
into the host cell membrane. As a result, fusion of the viral and host-cell endosomal 
membranes occurs. Upon fusion, the nucleocapsid, which carries virus RNA is 
released into the cytoplasm of the host cell (Lescar et al., 2008; Mukhopadhyay et 
al., 2005; Rawlinson et al., 2006). The capsid protein and viral RNA dissociation is 
probably a spontaneous process that occurred upon the release of nuclecapsid 
(Rawlinson et al., 2006). 
 
1.3.2.2 Translation and polyprotein processing 
 
In cytoplasm, the viral RNA served as mRNA that is directly translated into a 
long single polyprotein precursor of approximately 370 kDa. The polyprotein 
precursor is arranged in the order of NH2-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-
NS4B-NS5-COOH (Wahab et al., 2007). The polyprotein is then cleaved into the 
three viral structural (C-prM-E) and seven non-structural (NS1-NS2A-NS2B-NS3-
NS4A-NS4B-NS5) proteins by viral-encoded serine protease (NS2B-NS3), host cell 
proteases (signalase and furin) as well as other unknown protease (Lescar et al., 
2008; Mukhopadhyay et al., 2005; Rawlinson et al., 2006; Sampath & Padmanabhan, 
2009). 
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In addition to the ten proteins, two small hydrophobic peptides are released 
from the polyprotein (Figure 1.3). One is derived from the C-terminus of the 
anchored capsid protein; after the cleavage of this fragment, the mature capsid is 
released. The second one is a small fragment between the NS4A and the NS4B that 
is called 2K (Guzman, et al., 2006). 
 
The viral NS2B-NS3 protease is involved in the cleavage on the cytoplasmic 
side of the endoplasmic reticulum (ER) membrane whilst host cellular protease takes 
part in the cleavage in the ER lumen (Lescar et al., 2008). The viral NS2B-NS3 
protease is responsible for the cleavage at the NS2A/2B, NS2B/NS3, NS3/NS4A, 
NS4A/2K and NS4B/5. Host protease cleaves at the C/prM, prM/E, E/NS1 and 
2K/NS4B junctions (Figure 1.3) that release prM, E and NS1 proteins in the ER 
lumen (Guzman, et al., 2006; Rawlinson et al., 2006). 
 
1.3.2.3 RNA replication 
 
Genome replication occurs in intracellular membranes (Mukhopadhyay et al., 
2005) and Golgi-derived membranes called vesicle packed (Sampath & 
Padmanabhan, 2009). Non-structural proteins mediate the transcription of viral RNA. 
Thus, transcription started after the non-structural proteins have been synthesised and 
released from the polyprotein precursor (Lescar et al., 2008). Starting from the 
genomic plus-strand RNA, the complimentary negative-strand RNA is synthesised, 
which then served as the template for the production of an additional genomic plus-
strand RNA (Guzman, et al., 2006).  
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1.3.2.4 Viral assembly and release of new progeny virion 
 
Virus assembly occurs on the surface of the endoplasmic reticulum (ER) 
(Mukhopadhyay et al., 2005). The newly synthesised plus stranded RNA is coated 
with C protein to form nuclecapsid. The mechanism of interaction of the C protein in 
nucleocapsid is still not clear (Sampath & Padmanabhan, 2009). Then, E and prM 
envelop the nucleocapsid resulting in the formation of non-infectious, immature viral 
and subviral particles in the lumen of ER. Immature viral particle contains E and prM 
proteins, lipid membrane and nucleocapsid. On the other hand, subviral particle does 
not contain nucleocapsid. These particles are non-infectious as they cannot induce 
host-cell fusion. They are transported through the trans-Golgi network where the 
maturation of the virus particles occurs. In the trans-Golgi network, the prM is 
cleaved to M by the host protease furin and rearrangements of E protein occur, 
resulting in the formation of mature, infectious particles (Perera et al., 2008). 
Subviral particles are also cleaved by furin. Mature and subviral particles are 
subsequently released from the cell by exocytosis (Mukhopadhyay et al., 2005; 
Sampath & Padmanabhan, 2009). 
 
1.4 PROTEINS OF DENGUE VIRUS 
 
1.4.1 Structural proteins and functions 
 
The capsid protein (~100 amino acids) is involved in the packaging of viral 
genome/form nucleocapsid core (NC). The prM protein (~165 amino acids) might 
function as a chaperone for the folding and assembly of E protein during particle 
maturation. The E protein (~495 amino acids) constructs the envelope structure of 
the virus.  
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1.4.1.1 Capsid protein 
 
Dengue-2 virus capsid protein exists in dimer form and has been suggested to 
be the building block for nucleocapsid assembly. Nuclecapsid core formed in the 
early stage of assembly process, consists of one copy of genomic RNA and multiple 
copies of the capsid protein. However, NCs are rarely found in flavivirus-infected 
cells, which indicated that the particle formation is a coordinated process between the 
membrane-associated capsid protein and the prM-E heterodimers in the ER 
(Mukhopadhyay et al., 2005). The cryoEM reconstruction of mature and immature 
dengue virus show that the nucleocapsid is not a well-formed protein shell. It has 
been suggested that the capsid protein facilitates the binding of the nucleocapsid to 
the lipid membrane (Ma et al., 2004).  
 
1.4.1.2 E and M proteins 
 
The E protein, the external structural protein of dengue virus is responsible for 
the binding with cellular receptor and interacts with the host cell membrane for 
fusion and penetration, as well as viral assembly and budding. E protein also 
possesses antigenic determinants that elicit neutralizing antibodies (Huang et al., 
2008; Kuhn et al., 2002; Modis et al., 2004, 2005; Mukhopadhyay et al., 2005; 
Zhang et al., 2004). The ability of monoclonal antibody to neutralise dengue virus 
serotype 1, 2 and 3, is primarily by inhibiting the attachment to the host. Therefore, 
the change in viral surface structure was assumed to be responsible for inhibiting 
viral attachment to cell (Lok et al., 2008). 
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During the flavivirus life cycle, the virion exists in three main conformational 
states: immature, mature and fusion-activated. The conformation of the E protein 
differs in these three states. The conformational rearrangement occur from prM–E 
heterodimers in immature particle to E homodimers in the mature particle, and 
finally to E homotrimers in the fusion-activated particle (Perera et al., 2008).  
 
Following the assembly process, an immature virus particle is produced in 
ER, which have pre-membrane protein (prM) that must be proteolytically processed 
during virion maturation. There are two types of immature virus; “spiky” and 
“smooth” virus particles. Immature virus particles have a diameter of ∼600 Å 
(Figure 1.5A and 1.5C) with a spiky surface protein shell consisting of prM and E 
proteins, which form 180 heterodimers that are arranged as 60 trimeric spikes. 
Within each spike there are three prM-E heterodimers (Zhang et al., 2003; Zhang et 
al., 2004). The prM protein forms a cap-like structure that protects the fusion peptide 
on E protein and prevents the fusion of the virus with the host membrane. 
 
In Golgi apparatus, low pH environment trigger rotational and translational 
movement of E protein resulting in the transition of E protein from prM heterodimer 
(Figure 1.5C) to anti-parallel E homodimers (Figure 1.5D). The “smooth” viral 
morphology is formed but is still considered immature due to the presence of prM 
protecting the fusion peptide on E. Maturation process of flavivirus is directed by 
proteolitic cleavage of the precursor membrane protein (prM) (Li et al., 2008). Then, 
furin cleaves the prM into pr and M. The cleaved pr portion remains associated with 
E and is only released from the virus particle following the exit into neutral pH 
environment. Following maturation, the particle is released into a neutral 
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environment and pr peptide is released from the virion (Perera et al., 2008). 
 
 
Figure 1.5: Structure of flaviviruses. (A) A surface shaded view of the cryo-EM 
reconstruction of immature DENV-2 showing the spiky surface features. (B) A 
surface shaded view of the cryo-EM reconstruction of mature DENV-2 showing the 
relatively smooth surface features (C) Fit of the atomic coordinates of the E protein 
into the immature virus and (D) Mature virus showing the arrangement of the E 
proteins on the surface of the virion. Source: (Perera et al., 2008)  
 
Mature flavivirus particles (diameter ∼500 Å) have a relatively smooth 
surface with the lipid bilayer membrane completely covered by the envelope (E) and 
membrane (M) protein shell (Figure1.5B and 1.5D). This shell consists of 180 copies 
of the E protein arranged as 90 homodimers forming a herringbone pattern or so-
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called protein rafts that lie flat on the viral surface. Following the attachment of 
mature virus particle, specific cell-surface receptors mediate endocytosis of the virus. 
In the endosome, in the low pH environment, the E homodimers within the mature 
virion dissociate and re-arrange into fusion-active homotrimers. The fusion peptide 
of the virus becomes exposed at the distal end of the E protein and is inserted into the 
host membrane, which promotes fusion of the viral and host membranes (Modis et 
al., 2004; Perera et al., 2008). 
 
1.4.2 Non-structural proteins and functions 
 
Nonstructural proteins are essential for viral replication. NS1 involves in early 
steps of viral replication (Lindenbach & Rice, 1999), while NS3 shows enzymatic 
activities, which is involved in the viral polyprotein processing and genome 
replication. NS3 functions as a serine protease (NS2B-NS3 complex mediate 
proteolytic processing of polyprotein), 5’-RNA triphosphatase (RTPase), nucleoside 
triphosphatase (NTPase) and helicase (Luo et al., 2008). NS5 exhibits two enzymatic 
activities which are involved in the methylation of 5’-cap structure of genomic RNA 
(methyltransferase) and RNA-dependent RNA polymer (Dong et al., 2008; Geiss et 
al., 2009; Zhou et al., 2007). Due to the improved knowledge on the structures and 
functions of the proteins, the development of vaccine and therapeutic design 
currently target E, NS1, NS3 and NS5 proteins (Wahab et al., 2007). 
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1.4.2.1 Dengue virus NS2B-NS3 protease 
 
Proteins are made up of a long chains of amino acids that bonded by carbon-
nitrogen bonds called amide bonds or peptide bonds. Chemical hydrolysis of amide 
bond requires activation energy of ~25 kcal/mol. Therefore, under normal 
physiological conditions (pH~7, T = 37 °C), hydrolysis of amide bond would be very 
slow. However, catalysis of amide bond hydrolysis under physiological condition is 
accomplished at much faster rate by enzymes called proteases or peptidase.  
 
The protease or proteolytic enzymes not only catalyze protein hydrolysis at a 
fast rate but also specific and selective in order to prevent uncontrolled proteolysis of 
the organism. Proteases can be divided into classes based on their mechanism of 
action, which are serine, cysteine, aspartic, threonine and metallo proteases. As an 
example, a serine protease is an enzyme in which one of the amino acids at the active 
site is serine and the catalytic nucleophile in serine protease is hydroxyl group of the 
active site serine.  
 
Protease binds with the substrate in a specific manner that is represented by 
Schechter and Berger system of nomenclature. According to this system, the amino 
acid residues (or side chains) of substrate are labeled from the N to C terminus as 
Pn,.......,P3,P2,P1,P1’,P2’,P3’,........Pn’ and the corresponding binding sub sites of the 
enzyme are labelled as Sn,.......,S3,S2,S1,S1’,S2’,S3’,........Sn’. The peptide bond 
hydrolysis is carried out between  P1,P1’ and the bond is called the scissile bond 
(Figure 1.6). The P1 residue of the substrate is called the primary specificity residue. 
The specificity and selectivity of a protease depend on the nature of the P1 residue. 
As an example trypsin only cleaves at lysine or arginine residues (positively charged 
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residues/basic residues at P1). Serine proteases are classified as elastase-like (small 
hydrophobic residues at P1), trypsin-like (positively charged residues/basic residues 
at P1) or chymotripsin-like (large hydrophobic residues at P1). 
 
 
Figure 1.6: Schehter and Berger System of Nomenclature. 
 
NS2B-NS3 protease is a serine protease. Serine protease utilises a 
combination of mechanisms that are common to enzyme catalysis. First, enzyme 
binds to the substrate to form an enzyme-substrate Michaelis-Menten complex (E-S 
complex) utilizing non-covalent bonding interaction such as ionic interactions, 
dipole-dipole interactions, hydrophobic interactions, hydrogen bonding and Van der 
Waal’s interactions. When the substrate is bound to the active site of the enzyme, the 
carbonyl group of the scissile amide bond is exposed for catalysis by enzyme.  
 
The active site of serine protease consists of three conserved amino acid 
residue; serine, histidine and aspartic acid that together form the “catalytic triad”. 
Serine protease utilises an active site serine residue in a covalent catalytic cleavage 
of peptide bonds. Nucleophilic group of serine is hydroxyl, which is a poor 
nucleophile. However, the serine hydroxyl is activated by general base catalysis 
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through hydrogen bonding network involving aspartic acid, histidine and serine 
residues nearby. This process converts serine to alkoxide (ionised serine) through a 
mechanism called the charge relay system (Silverman, 2004). The active site of 
serine (activated nucleophile) then attacks the carbonyl group of the scissile amide 
bond (Figure 1.7). 
 
 
Figure 1.7: Charge relay system for activation of an active site serine residue.  
 
Dengue NS3 protein is made up of 618 amino acids. It consists of two 
domains that possess enzymatic activity: a trypsin-like serine protease located in the 
N-terminal domain of the protein and a C-terminal domain that possess RNA 
helicase and NTPase activity (Murthy et al., 1999). The NS3 protease domain adopts 
a chymotrypsin-like fold with two β-barrels, each formed by six β-strands 
(Figure1.8), with the catalytic triad (His51-Asp75-Ser135) located at the cleft 
between the two β-barrels. 
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Figure 1.8: Structures of NS2B–NS3 protease (Blue, NS3pro; Green, NS2B). 
Residues of the catalytic triad Histidine 51 (HIS 51), Aspartate 75 (ASP 75) and 
Serine 135 (SER 135) are shown as red-colored stick models. Source: (Wichapong et 
al., 2009). 
 
It has been reported that Dengue virus NS3 protease alone is not active for 
proteolysis. The enzymatic activity of NS3 protease is enhanced by its interaction 
with NS2B protein (130 amino acid) that functions as a co-factor. Both NS2B and 
NS3 are required for proteolytic processing of dengue virus polyprotein (Falgout et 
al., 1991). From the X-ray crystal structure of NS2B (PDB ID: 2FOM) (Erbel et al., 
2006), residues 51-57 of NS2B form a β-strand which associates with the NS3 
protease. Erbel et al. (2006) also expressed a construct containing residues 49–66 of 
NS2B in a soluble form, indicating that the N-terminal part of NS2B is sufficient to 
stabilise the enzyme. However, the truncated NS2B-NS3 protein is catalytically 
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inactive and cannot bind a substrate-based inhibitor, which suggests that the C-
terminal part of NS2B directly interacts with the substrate-binding site. This is in 
contrast to HCV NS3 protease, where a short fragment of NS4A, including residues 
corresponding to β-strand 1, is sufficient to yield a fully active enzyme (Erbel et al., 
2006). 
 
It is also suggested that NS2B functions as a chaperone in assisting the 
folding of NS3 protease to an active conformation (Leung et al., 2001). A 47-
residues central hydrophobic region of NS2B is found to be essential for the 
activation of NS3 protease where the absence of NS2B has adverse effects on both 
the stability and the catalytic activity of NS3 protease (Murthy et al., 1999; Yusof et 
al., 2000).  Leung et al. (2001) also reported that the enzyme is inactive on its own or 
after the addition of 13-residues cofactor but is active when fused to the 40-residues 
cofactor. The first homology model with complete structure of the protease including 
the complete cofactor NS2B in the productive form was presented by Wichapong et 
al. (2009). 
 
The active site of NS2B-NS3 protease consists of four pockets, which are S1, 
S2, S3 and S4 that interact with the substrate residues P1, P2, P3 and P4, 
respectively. The sequence alignment of Dengue 2 Virus (PDB ID: 2FOM) and West 
Nile Virus (2PF7) of NS2B and NS3 domains (Erbel et al., 2006) showed that all 
residues in the pockets are either identical or similar for these two viruses 
(Wichapong et al., 2009) as shown in the Figure 1.9.  
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Figure 1.9: Sequence alignment of DENV and WNV NS2B and NS3 domains. Stars 
indicate residues that are identical whereas dots and colons indicate similar residues. 
Residues which are drawn italic and underlined are missing residues in the X-ray 
structures. Residues located in the S1, S2, S3, and S4 pockets are colored cyan, 
yellow, green, and magenta, respectively, and catalytic triads are displayed in bold 
red. Source: (Wichapong et al., 2009). 
 
Previous alignment studies indicated that NS3 protease has structurally 
similar to trypsin-like serine protease (Murthy et al., 1999). However, unlike trypsin, 
NS3 protease has a marked preference for a pair of basic residues (either Arg or Lys) 
at P2 and P1 in its peptide substrate followed by a small, unbranch amino acid (Gly 
or Ser) at P1’ (Chambers et al., 1991; Chambers et al., 1990)   
 
Wichapong and co-workers (2009) had constructed homology model of DEN-
2 Virus NS2B-NS3 protease complexed with the peptidic inhibitor (Bz-Nle-Lys-Arg-
Arg-H).  Based on the MD simulation of this homology model, the interactions 
between the enzyme active sites and inhibitors were revealed. It was suggested that 
His51 and Asp129 of NS3 protease play significant role in stabilizing the basic 
inhibitor P1 residue Arg or Lys (Li et al., 2005; Wichapong et al., 2009). From the 
simulation, the interaction of Arg-P2 and residues Asp75 (C-terminus NS2B), 
Asn152 (NS3) and Gly182 (NS2B) were observed. This result suggested that C-
terminus of NS2B not only play an important role for stabilizing and reorganizing the 
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NS3 protease but is also essential for the interaction with P2 residue of the inhibitor. 
 
All residues in S3 pocket are made up from NS2B domain. MD simulation 
showed that the H-bond was only observed between Lys-P3 and Tyr161. The S4 
pocket of DEN-2 protease is formed by Val154, Val155, Thr156 and Arg157 
suggested that it is dominated by hydrophobic residues. Thus the preferred residue at 
the P4 position of peptidic inhibitor is norleucine or leucine (Li et al., 2005). 
Wichapong and co-workers (2009) also revealed that the hydrogen bond between 
Nle-P4 of inhibitor and the S4 pocket is very low. 
 
1.4.2.2 Dengue virus NS2B-NS3 protease as a potential drug target 
 
The replication of flaviviruses requires the correct processing of their 
polyprotein by the viral NS2B-NS3 protease. Therefore, NS2B-NS3  protease is a  
potential target for the development of therapeutics against the dengue virus 
(Tomlinson et al., 2009). Moreover, protease inhibitors have a successful history as 
being developed into antiviral drugs (Hsu et al., 2006; Malcolm et al., 2006; 
Wlodawer & Vondrasek, 1998). A few protease inhibitors have been approved by 
US Food and Drug Administration (FDA) for HIV treatement such as saquinavir 
mesylate (1995), ritonavir (1996) and indinavir (1996), amprenavir (1999) and 
atazanavir sulphate (2003) (Hsu et al., 2006). For dengue virus, the potential peptides 
and small molecules as protease inhibitors have been studied by a few reserchers 
focusing on NS2B-NS3 protease (Chanprapaph et al., 2005; Ganesh et al., 2005; Kiat 
et al., 2006; Yin et al., 2006a). 
 
 
